Resources

Resources

2023 Biosimilars Report

How will biosimilars impact the U.S. healthcare market in 2023? Cardinal Health researchers analyze new and changing perspectives of some of the most disruptive biosimilars launched in the areas of immunology and ophthalmology in the 2023 Biosimilars Report: tracking market expansion and sustainability amidst a shifting industry. Access the link here

Surveying more than 350 providers across rheumatology, ophthalmology, gastroenterology, and dermatology, this report offers new analysis, insights into market growth, drivers of adoption, and obstacles that remain. With an updated analysis of biosimilar market adoption and key milestones achieved throughout 2022, Cardinal Health experts discuss how policy and updated formulary announcements may impact patient access to these critical therapeutics.

Rheumatology Products Requiring Dilution Reference Guide

To access the “Rheumatology Products Requiring Dilution Reference Guide” Click Here

ISMP and ASHP Guidance

ISMP and ASHP have written some guidance for handling the current fluid and drug shortages and highlight some of the safety issues with trying to substitute fluids outside of package insert instructions that may be an additional helpful resource. Access the links below.

“Small Volume Parental Solutions Shortages” – ASHP: Click Here

“Management of Drug Shortages with 0.9% Sodium Chloride, Sterile Water for Injection and EPINEPHrine” -ISMP: Click Here

Understand your state’s laws for interchangeable biosimilars

Given the robust pipeline of Humira biosimilars and additional biosimilars with rheumatology indications that are anticipated to become FDA approved starting in 2023, it’s important to understand your own state’s laws on biologic interchangeability to prepare for this change. To help your practice navigate your state’s specific guidelines and support patients with biosimilar adoption, Cardinal Health collaborated with regulatory advisors to develop a state-by-state resource to help you understand the various biosimilar interchangeability laws. You can also access additional biosimilar related articles and resources to keep you up to date on the Cardinal Health Biosimilars website

Watch NORM and Cardinal Health’s April Webinar on Supply Shortage below!

Access the Recording Here